U.S. markets open in 6 hours 51 minutes
  • S&P Futures

    4,505.00
    -6.25 (-0.14%)
     
  • Dow Futures

    35,279.00
    -44.00 (-0.12%)
     
  • Nasdaq Futures

    15,372.50
    -26.00 (-0.17%)
     
  • Russell 2000 Futures

    2,268.20
    -4.60 (-0.20%)
     
  • Crude Oil

    82.40
    -0.56 (-0.68%)
     
  • Gold

    1,776.20
    +5.70 (+0.32%)
     
  • Silver

    23.91
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1644
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.6350
    0.0000 (0.00%)
     
  • Vix

    15.70
    -0.61 (-3.74%)
     
  • GBP/USD

    1.3786
    -0.0008 (-0.06%)
     
  • USD/JPY

    114.5000
    +0.1400 (+0.12%)
     
  • BTC-USD

    63,789.89
    +1,553.63 (+2.50%)
     
  • CMC Crypto 200

    1,477.23
    +13.87 (+0.95%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 49% Undervaluation?

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

How far off is Atlas Arteria Limited (ASX:ALX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the forecast future cash flows of the company and discounting them back to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.

See our latest analysis for Atlas Arteria

Step by step through the calculation

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF (A$, Millions)

AU$478.3m

AU$578.7m

AU$624.2m

AU$654.0m

AU$694.8m

AU$725.8m

AU$752.7m

AU$776.6m

AU$798.3m

AU$818.5m

Growth Rate Estimate Source

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Analyst x1

Est @ 4.47%

Est @ 3.71%

Est @ 3.17%

Est @ 2.8%

Est @ 2.53%

Present Value (A$, Millions) Discounted @ 7.6%

AU$444

AU$500

AU$501

AU$487

AU$481

AU$467

AU$450

AU$431

AU$412

AU$392

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = AU$4.6b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.6%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = AU$819m× (1 + 1.9%) ÷ (7.6%– 1.9%) = AU$15b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= AU$15b÷ ( 1 + 7.6%)10= AU$7.0b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is AU$12b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of AU$6.1, the company appears quite good value at a 49% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Atlas Arteria as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.6%, which is based on a levered beta of 1.209. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For Atlas Arteria, we've compiled three additional aspects you should further examine:

  1. Risks: As an example, we've found 2 warning signs for Atlas Arteria (1 can't be ignored!) that you need to consider before investing here.

  2. Future Earnings: How does ALX's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. Simply Wall St updates its DCF calculation for every Australian stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.